These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

150 related items for PubMed ID: 21918035

  • 1. Utility of P-glycoprotein and organic cation transporter 1 double-transfected LLC-PK1 cells for studying the interaction of YM155 monobromide, novel small-molecule survivin suppressant, with P-glycoprotein.
    Iwai M, Minematsu T, Li Q, Iwatsubo T, Usui T.
    Drug Metab Dispos; 2011 Dec; 39(12):2314-20. PubMed ID: 21918035
    [Abstract] [Full Text] [Related]

  • 2. Characterization of human organic cation transporter 1 (OCT1/SLC22A1)- and OCT2 (SLC22A2)-mediated transport of 1-(2-methoxyethyl)-2-methyl-4,9-dioxo-3-(pyrazin-2-ylmethyl)- 4,9-dihydro-1H-naphtho[2,3-d]imidazolium bromide (YM155 monobromide), a novel small molecule survivin suppressant.
    Minematsu T, Iwai M, Umehara K, Usui T, Kamimura H.
    Drug Metab Dispos; 2010 Jan; 38(1):1-4. PubMed ID: 19833842
    [Abstract] [Full Text] [Related]

  • 3. Involvement of human organic cation transporter 1 in the hepatic uptake of 1-(2-methoxyethyl)-2-methyl-4,9-dioxo-3-(pyrazin-2-ylmethyl)-4,9-dihydro-1H-naphtho[2,3-d]imidazolium bromide (YM155 monobromide), a novel, small molecule survivin suppressant.
    Iwai M, Minematsu T, Narikawa S, Usui T, Kamimura H.
    Drug Metab Dispos; 2009 Sep; 37(9):1856-63. PubMed ID: 19520775
    [Abstract] [Full Text] [Related]

  • 4. Carrier-mediated uptake of 1-(2-methoxyethyl)-2-methyl-4,9-dioxo-3-(pyrazin-2-ylmethyl)-4,9-dihydro-1H-naphtho[2,3-d]imidazolium bromide (YM155 monobromide), a novel small-molecule survivin suppressant, into human solid tumor and lymphoma cells.
    Minematsu T, Iwai M, Sugimoto K, Shirai N, Nakahara T, Usui T, Kamimura H.
    Drug Metab Dispos; 2009 Mar; 37(3):619-28. PubMed ID: 19056913
    [Abstract] [Full Text] [Related]

  • 5. Specificity of doxorubicin versus rhodamine-123 in assessing P-glycoprotein functionality in the LLC-PK1, LLC-PK1:MDR1 and Caco-2 cell lines.
    van der Sandt IC, Blom-Roosemalen MC, de Boer AG, Breimer DD.
    Eur J Pharm Sci; 2000 Sep; 11(3):207-14. PubMed ID: 11042226
    [Abstract] [Full Text] [Related]

  • 6. P-glycoprotein mediates efflux transport of darunavir in human intestinal Caco-2 and ABCB1 gene-transfected renal LLC-PK1 cell lines.
    Fujimoto H, Higuchi M, Watanabe H, Koh Y, Ghosh AK, Mitsuya H, Tanoue N, Hamada A, Saito H.
    Biol Pharm Bull; 2009 Sep; 32(9):1588-93. PubMed ID: 19721237
    [Abstract] [Full Text] [Related]

  • 7. Differences in the expression of endogenous efflux transporters in MDR1-transfected versus wildtype cell lines affect P-glycoprotein mediated drug transport.
    Kuteykin-Teplyakov K, Luna-Tortós C, Ambroziak K, Löscher W.
    Br J Pharmacol; 2010 Jul; 160(6):1453-63. PubMed ID: 20590635
    [Abstract] [Full Text] [Related]

  • 8. Vectorial transport of the plant alkaloid berberine by double-transfected cells expressing the human organic cation transporter 1 (OCT1, SLC22A1) and the efflux pump MDR1 P-glycoprotein (ABCB1).
    Nies AT, Herrmann E, Brom M, Keppler D.
    Naunyn Schmiedebergs Arch Pharmacol; 2008 Feb; 376(6):449-61. PubMed ID: 18157518
    [Abstract] [Full Text] [Related]

  • 9. Interactions of attention-deficit/hyperactivity disorder therapeutic agents with the efflux transporter P-glycoprotein.
    Zhu HJ, Wang JS, Donovan JL, Jiang Y, Gibson BB, DeVane CL, Markowitz JS.
    Eur J Pharmacol; 2008 Jan 14; 578(2-3):148-58. PubMed ID: 17963743
    [Abstract] [Full Text] [Related]

  • 10. Creation of polarized cells coexpressing CYP3A4, NADPH cytochrome P450 reductase and MDR1/P-glycoprotein.
    Brimer C, Dalton JT, Zhu Z, Schuetz J, Yasuda K, Vanin E, Relling MV, Lu Y, Schuetz EG.
    Pharm Res; 2000 Jul 14; 17(7):803-10. PubMed ID: 10990198
    [Abstract] [Full Text] [Related]

  • 11. Role of P-glycoprotein in the efflux of raltegravir from human intestinal cells and CD4+ T-cells as an interaction target for anti-HIV agents.
    Hashiguchi Y, Hamada A, Shinohara T, Tsuchiya K, Jono H, Saito H.
    Biochem Biophys Res Commun; 2013 Sep 20; 439(2):221-7. PubMed ID: 23981805
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Directional transcellular transport of bisoprolol in P-glycoprotein-expressed LLC-GA5-COL150 cells, but not in renal epithelial LLC-PK1 Cells.
    Tahara K, Kagawa Y, Takaai M, Taguchi M, Hashimoto Y.
    Drug Metab Pharmacokinet; 2008 Sep 20; 23(5):340-6. PubMed ID: 18974611
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Effects of MDR1 1236C > T-2677G > T-3435C > T polymorphisms on the intracellular accumulation of tacrolimus, cyclosporine A, sirolimus and everolimus.
    Wang R, Sun X, Deng YS, Qiu XW.
    Xenobiotica; 2019 Nov 20; 49(11):1373-1378. PubMed ID: 30587068
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Intestinal absorption mechanism of mirabegron, a potent and selective β₃-adrenoceptor agonist: involvement of human efflux and/or influx transport systems.
    Takusagawa S, Ushigome F, Nemoto H, Takahashi Y, Li Q, Kerbusch V, Miyashita A, Iwatsubo T, Usui T.
    Mol Pharm; 2013 May 06; 10(5):1783-94. PubMed ID: 23560393
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.